Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAPLON vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
RAPLON (levosimendan) is a calcium sensitizer that increases myocardial contractility by sensitizing troponin C to calcium, and it also opens ATP-sensitive potassium channels, causing vasodilation.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Short-term treatment of acutely decompensated chronic heart failure (NYHA III-IV) in patients with low cardiac output refractory to standard therapy,Off-label: Management of low cardiac output syndrome after cardiac surgery,Off-label: Treatment of cardiogenic shock
Hypertension
0.2 mg/kg IV bolus over 30 seconds; may repeat once if necessary after 15 minutes.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Terminal elimination half-life is approximately 1.5-2.5 hours in patients with normal renal function; prolonged in renal impairment (up to 6-8 hours in end-stage renal disease).
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Primarily metabolized by the liver via conjugation to a methyl ester, which is then further conjugated by glutathione-S-transferase. The active metabolite (OR-1896) has a long half-life.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Primarily renal excretion of unchanged drug (approximately 80-90% of administered dose within 24 hours); minor biliary/fecal elimination (less than 10%).
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Approximately 30-40% bound to plasma proteins, primarily albumin.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Volume of distribution is approximately 0.2-0.3 L/kg, indicating distribution primarily into extracellular fluid.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Intravenous: 100% (only route used clinically). Intramuscular: Not routinely used; bioavailability data limited.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
No dose adjustment required; RAPLON is not significantly renally eliminated.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh A and B: no adjustment; Child-Pugh C: use with caution, consider reducing dose by 50% due to prolonged duration.
Child-Pugh Class B or C: contraindicated; use not recommended.
0.2 mg/kg IV bolus over 30 seconds; maximum single dose 10 mg; may repeat once after 15 minutes.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Use 0.15 mg/kg IV bolus over 30 seconds due to increased sensitivity and risk of prolonged neuromuscular blockade.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None
None
Hypotension; tachyarrhythmias; renal impairment; electrolyte disturbances (hypokalemia, hypomagnesemia) may increase risk of arrhythmias; monitoring of blood pressure, heart rate, and ECG required; not recommended in severe hepatic impairment.
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Hypersensitivity to levosimendan or any excipient; severe hypotension (systolic BP < 85 mm Hg); severe tachyarrhythmia; significant mechanical obstruction affecting ventricular filling or outflow; history of torsades de pointes; severe renal impairment (Cr Cl < 30 m L/min); severe hepatic impairment.
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Grapefruit and grapefruit juice may increase the effects and prolong paralysis. Clarithromycin, itraconazole, and other CYP3A4 inhibitors can enhance duration. Avoid high-fat meals shortly before use as they may delay onset.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
Pregnancy Category C. No adequate human studies. Trimester 1: Risk of fetal malformations cannot be ruled out; animal studies show decreased fetal weight at maternally toxic doses. Trimester 2-3: Potential for fetal respiratory depression or apnea when used near term; avoid during labor.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Not recommended. No human data available on excretion into breast milk. M/P ratio unknown.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
No dose adjustment required; however, increased clearance in late pregnancy may necessitate higher doses, but clinical significance unknown.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
RAPLON (rapacuronium) is a rapid-onset, short-duration nondepolarizing neuromuscular blocker. It produces paralysis within 60-90 seconds and lasts 15-20 minutes. Avoid in patients with significant hepatic or renal impairment. Use with caution in elderly and those with electrolyte imbalances. Reversal with neostigmine is effective but may require higher doses. Monitor for histamine release and bronchospasm, especially in asthmatics.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
This medication causes complete paralysis, including inability to breathe, so you will be on a breathing machine.,Tell your doctor if you have asthma, liver or kidney disease, or any allergies.,Inform your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.,You may experience temporary muscle weakness after the drug wears off.,Avoid grapefruit and grapefruit juice before and after procedure.,Report any difficulty breathing, rash, or itching immediately.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAPLON vs ALDORIL D30, answered by our medical review team.
RAPLON is a Antihypertensive that works by RAPLON (levosimendan) is a calcium sensitizer that increases myocardial contractility by sensitizing troponin C to calcium, and it also opens ATP-sensitive potassium channels, causing vasodilation.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAPLON and ALDORIL D30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAPLON is: 0.2 mg/kg IV bolus over 30 seconds; may repeat once if necessary after 15 minutes.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAPLON and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAPLON is classified as Category C. Pregnancy Category C. No adequate human studies. Trimester 1: Risk of fetal malformations cannot be ruled out; animal studies show decreased fetal weight at maternally toxic doses.. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.